Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT03380442

Organisation Name: University of Helsinki

Overal Status: Not yet recruiting

Start Date: September 2018

Last Update: December 21, 2017

Lead Sponsor: University of Helsinki

Brief Summary: The main aim of the study is to investigate the possible long-term therapeutic effects of psilocybin on the symptoms of severe depression, as well as the brain mechanisms underlying these changes. Depression severity is assessed before and after (i.e., 1 week, 3 months and 6 months after) a single dose of psilocybin and compared to respective scores of a group receiving an active placebo, ketamine. Brain activity (using functional magnetic resonance imaging) is measured before and one week after drug administration in order to determine whether changes in brain networks related to emotional and self-referential processing correlate with any observed changes in depression scores. Further, blood samples will be obtained from the participants and analyzed in order to reveal gene expression and molecular level correlates underlying rapid antidepressant effects, and to identify biomarkers that predict treatment outcome.

Conditions:
  • Severe Depression


Total execution time in seconds: 0.20412993431091